stockmarketquotes

Related USO Does Being An Oil Bear Make You A Nat Gas Bull? Jim Iurio Is Bullish On Crude Oil

The price of a barrel of oil hit a two-year high in reaction to Saudi Arabia's anti-corruption purge, which saw the arrest of well-known billionaire investor Prince Al-Waleed bin Talal.

The Analyst

Bank of America Merrill Lynch's head of global commodities Francisco Blanch.

The Strategy

Buying oil amid geopolitical risks and concerning headlines may be a mistake, Blanch said. 

The Thesis

The price of oil has been trading near the $50 mark for most of 2017 but has now jumped above $60 per barrel, mostly due to Saudi Arabia's anti-corruption purge. Investors are now questioning if the price of oil is fully factoring in geopolitical risk, or if the commodity should trade higher. The short answer: oil is bad at pricing in geopolitical risk, Blanch said. 

stockmarketquotes: CoreSite Realty Corporation(COR)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Denver, Colorado-based CoreSite Realty Corporation (COR) offers cloud-enabled, high-performance data center campuses.

    Operating across 17 data centers in eight key North American markets, CoreSite serves a broad range of clients, including telecommunications carriers, media companies, financial and educational institutions, and government agencies.

stockmarketquotes: Comp En De Mn Cemig ADS(CIG)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday afternoon, the utilities sector proved to be a source of strength for the market. Leading the sector was strength from Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG) and Pampa Energia S.A. (ADR) (NYSE: PAM).

  • [By Lisa Levin]

    In trading on Monday, utilities shares fell 0.66 percent. Meanwhile, top losers in the sector included RGC Resources Inc. (NASDAQ: RGCO), down 5 percent, and Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG), down 5 percent.

  • [By Lisa Levin]

    In trading on Friday, utilities shares fell by 0.33 percent. Meanwhile, top losers in the sector included Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG), down 3 percent, and Companhia Paranaense de Energia (ADR) (NYSE: ELP), down 3 percent.

  • [By Lisa Levin]

    Non-cyclical consumer goods & services sector was the top gainer in the US market on Wednesday. Top gainers in the sector included Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG), Companhia Paranaense de Energia (ADR) (NYSE: ELP), and NRG Energy Inc (NYSE: NRG).

stockmarketquotes: Vanguard Extended Duration Treasury ETF (EDV)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    The 11 ETF fee cuts unveiled by Vanguard include a significant portion of the issuer's fixed income lineup. All of the following saw annual fees reduced to 0.07 percent from 0.1 percent:

    Vanguard Extended Duration Treasury ETF (NYSE: EDV). Vanguard Intermediate-Term Bond ETF (NYSE: BIV). Vanguard Intmdte Tm Govt Bd ETF (NASDAQ: VGIT). Vanguard Long Term Corporate Bond ETF (NASDAQ: VCLT). Vanguard Lg Term Govt Bd ETF (NASDAQ: VGLT). Vanguard Mortgage Bkd Sects ETF (NASDAQ: VMBS).

    and the Vanguard Short Term Corporate Bond ETF (NASDAQ: VCSH).

stockmarketquotes: Novo Nordisk A/S(NVO)

Advisors’ Opinion:

  • [By Paul Ausick]

    Novo Nordisk A/S (NYSE: NVO) dropped about 1.5% on Friday to post a new 52-week low of $32.35 after closing at $32.84 on Thursday. The stock’s 52-week high is $59.00. Volume of about 3.4 million was close to the daily average of around 3.9 million shares. The drug maker had no specific news.

  • [By Keith Speights]

    Eisai (NASDAQOTH:ESALY), Novo Nordisk (NYSE:NVO), and Roche Holding Ltd. (NASDAQOTH:RHHBY) fit that description well. Each of these companies markets obesity drugs, but each also sells a broad array of other products with multiple pipeline candidates potentially on the way. Here’s why Eisai, Novo Nordisk, and Roche rank as the three best obesity-drug stocks to buy in 2017.

  • [By Brian Orelli]

    Global Blood Therapeutics (NASDAQ:GBT) is up 20% at 3:42 p.m. EST after Reuters reported that Novo Nordisk (NYSE:NVO) has approached the biotech about a potential acquisition.

  • [By Peter Graham]

    A long term performance chart shows MannKind Corporation having once been a highflyerwhile the performance of large cap insulin and diabetes stockNovo Nordisk A/S (NYSE: NVO) has fallen off and small cap Insulet Corporation (NASDAQ: PODD) has actually performed better:

  • [By James E. Brumley]

    When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.

    In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.

    While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.

    As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’

stockmarketquotes: Signet Jewelers Limited(SIG)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of Tiffany & Co heading back towards late 2014 highs while mid capSignet Jewelers Ltd (NYSE: SIG) peaked in late 2015 andhas largely fallen off since then:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Signet Jewelers Limited (NYSE: SIG) which jumped 8.8% to $70.06. The gain was following news that the company had a solid earnings report. The stocks 52-week range is $62.10 to $125.45. Volume was 7.48 million which is well above the daily average of around 1.69 million shares.

  • [By Peter Graham]

    A long term performance chart shows shares of Tiffany & Co heading back towards late 2014 highs while mid capSignet Jewelers Ltd (NYSE: SIG) peaked in late 2015 andhas continued to fall off since then:

stockmarketquotes: SPDR Blmbg Barclays Intl Trs Bd ETF (BWX)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    DWFI also holds the SPDR Barclays Emerging Markets Local Bond ETF (NYSE: EBND), SPDR Barclays International Treasury Bond ETF (NYSE: BWX) and the SPDR Barclays Intermediate Term Corporate Bond ETF (NYSE: ITR).

Leave a Reply

Your email address will not be published. Required fields are marked *